Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
FATE THERAPEUTICS INC (FATE)
|
Add to portfolio |
|
|
|
| Price: |
$78.91
| | Metrics |
| OS: |
98.6
|
M
| |
-45
|
% ROE
|
| Market cap: |
$7.78
|
B
| |
-53
|
% ROIC
|
|
Net cash:
|
$46.8
|
M
| |
$0.47
|
per share
|
|
EV:
|
$7.73
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($260)
|
M
| |
|
|
| EPS |
($2.52)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 96.3 | 55.8 | 215.5 | 31.4 | 125.6 | 10.7 | 4.7 | 4.1 |
| Revenue growth | 72.4% | 77.7% | 71.6% | 194.3% | | 125.3% | 15.4% | -6.7% |
| Cost of goods sold | 0.0 | 0.0 | 375.2 | 0.0 | 219.8 | 0.0 | 0.0 | 0.0 |
| Gross profit | 96.3 | 55.8 | -159.7 | 31.4 | -94.2 | 10.7 | 4.7 | 4.1 |
| Gross margin | 100.0% | 100.0% | -74.1% | 100.0% | -75.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 404.7 | 272.8 | | 159.5 | | 111.4 | | |
| Research and development | | | | | | | 56.0 | 34.4 |
| General and administrative | | | 57.3 | | 33.9 | | 15.8 | 11.9 |
| EBIT | -282.2 | -212.2 | -217.0 | -173.4 | -128.1 | -100.7 | -67.1 | -42.1 |
| EBIT margin | -293.1% | -379.9% | -100.7% | -551.6% | -102.0% | -943.1% | -1415.4% | -1025.9% |
| Pre-tax income | -281.7 | -212.2 | -212.2 | -173.4 | -173.4 | -98.1 | -66.6 | -43.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -281.7 | -212.2 | -212.2 | -173.4 | -173.4 | -98.1 | -66.6 | -43.0 |
| Net margin | -292.5% | -379.9% | -98.4% | -551.6% | -138.0% | -919.0% | -1405.0% | -1046.1% |
| |
| Diluted EPS | ($2.91) | ($2.24) | ($2.24) | ($2.10) | ($2.10) | ($1.44) | ($1.19) | ($1.02) |
| Shares outstanding (diluted) | 96.8 | 94.7 | 94.7 | 82.4 | 82.6 | 68.2 | 56.2 | 42.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|